Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized, open-label, multiple-dose study to evaluate the effect of omeprazole 20 mg on the pharmacokinetics of atazanavir administered with ritonavir in healthy subjects

X
Trial Profile

Randomized, open-label, multiple-dose study to evaluate the effect of omeprazole 20 mg on the pharmacokinetics of atazanavir administered with ritonavir in healthy subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 21 Apr 2011

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atazanavir (Primary) ; Omeprazole (Primary) ; Ritonavir (Primary)
  • Indications Duodenal ulcer; Dyspepsia; Gastric ulcer; Gastritis; Gastro-oesophageal reflux; Gastrointestinal disorders; HIV-1 infections; Peptic ulcer; Zollinger-Ellison syndrome
  • Focus Pharmacokinetics
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 07 Apr 2011 Actual end date (1 Aug 2006) added as reported by ClinicalTrials.gov.
    • 10 May 2010 Results published in the Journal of Clinical Pharmacology.
    • 02 Nov 2006 New trial record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top